You are here

  • Home
  • Online First
  • Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination

Article info

Article menu

Download PDFPDF

Adverse drug reactions
Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination
Free

Authors

  • Adrian Y S Lee Westmead Hospital, Westmead, New South Wales, AustraliaDepartment of Immunopathology, Institute for Clinical Pathology and Medical Research & NSW Health Pathology, Westmead, NSW, AustraliaWestmead Clinical School, The University of Sydney, Westmead, NSW, Australia PubMed articlesGoogle scholar articles
  • Caroline Lee Westmead Hospital, Westmead, New South Wales, Australia PubMed articlesGoogle scholar articles
  • David A Brown Westmead Hospital, Westmead, New South Wales, AustraliaDepartment of Immunopathology, Institute for Clinical Pathology and Medical Research & NSW Health Pathology, Westmead, NSW, AustraliaWestmead Clinical School, The University of Sydney, Westmead, NSW, Australia PubMed articlesGoogle scholar articles
  • Dan Suan Westmead Hospital, Westmead, New South Wales, AustraliaWestmead Clinical School, The University of Sydney, Westmead, NSW, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Adrian Y S Lee; adrian.lee1{at}health.nsw.gov.au
View Full Text

Citation

Lee AYS, Lee C, Brown DA, et al
Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination
Postgraduate Medical Journal Published Online First: 07 February 2022. doi: 10.1136/postgradmedj-2022-141510

Publication history

  • Received January 3, 2022
  • Accepted January 22, 2022
  • First published February 7, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage